TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37732619

Group type: EXPERIMENTAL
Intervention: Low-dose lithium treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37732745

Group type: EXPERIMENTAL
Intervention: Microsurgical clipping of UIA (benchmark cohort)
Number of subjects: 2245
Study: 37732786

Group type: EXPERIMENTAL
Intervention: Tanshinone I
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37732961

Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts-extended release (MAS-ER) 80 mg/day for 10 weeks
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo 80 mg/day for 10 weeks
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts-extended release (MAS-ER)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 37732972

Group type: EXPERIMENTAL
Intervention: Mood Lifters for Graduate Students (ML-GS)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 131
Study: 37732990

Group type: EXPERIMENTAL
Intervention: Aldafermin 3 mg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Aldafermin 1 mg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 37733083

Group type: EXPERIMENTAL
Intervention: Adhesix™ mesh
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Progrip™ mesh
Number of subjects: 270
Study: 37733159

Group type: EXPERIMENTAL
Intervention: Hypoglycemia (2.8 mmol/L, 50 mg/dL) during PM clamp
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hypoglycemia (2.8 mmol/L, 50 mg/dL) during AM clamp
Number of subjects: 16

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Insulin levels
Number of subjects: 16
Study: 37733189

Group type: EXPERIMENTAL
Intervention: Full RHC intervention
Number of subjects: 169

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 169
Study: 37733309

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus Trametinib
Number of subjects: 110

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 110
Study: 37733308

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone furoate (200 μg once daily for 14 days)
Number of subjects: 1407

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1407

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone furoate
Number of subjects: 1407

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone furoate and Placebo
Number of subjects: 1407
Study: 37733345

Group type: EXPERIMENTAL
Intervention: Lower hemoglobin threshold group
Number of subjects: 179

Group type: COMPARATOR
Intervention: Higher hemoglobin threshold group
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Pretransfusion Csat less than 50%
Number of subjects: 179
Study: 37733356

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 37733364

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB)
Number of subjects: 1405

Group type: COMPARATOR
Intervention: No axillary surgery
Number of subjects: 1405

Group type: EXPERIMENTAL
Intervention: SLNB
Number of subjects: 1405
Study: 37733479

Group type: EXPERIMENTAL
Intervention: iCC-SCD (digital cognitive-behavioral therapy program)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Education control
Number of subjects: 137
Study: 37733487

Group type: EXPERIMENTAL
Intervention: 6-session telephone-delivered intervention to increase patient activation
Number of subjects: 250

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 250
Study: 37733666

Group type: EXPERIMENTAL
Intervention: Nicotine flux with varying forms (freebase vs protonated) in Trial I
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine flux with varying forms in Trial II
Number of subjects: 0
Study: 37733724

Group type: EXPERIMENTAL
Intervention: Live attenuated mumps vaccine
Number of subjects: 10057
Study: 37733966

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.25% ophthalmic suspension, 4 times daily for 2 months, tapered to once daily for 10 months
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate 0.25% ophthalmic suspension
Number of subjects: 70

Group type: COMPARATOR
Intervention: Historical data (loteprednol 0.5% gel)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Historical data (prednisolone 1% suspension)
Number of subjects: 70
Study: 37733977

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate and prednisone (AAP) with concomitant stereotactic body radiation therapy (SBRT)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Abiraterone acetate and prednisone (AAP) alone
Number of subjects: 157
Study: 37733980

Group type: EXPERIMENTAL
Intervention: Video Education (VE)
Number of subjects: 662

Group type: COMPARATOR
Intervention: Genetic Counseling (GC)
Number of subjects: 662

Group type: EXPERIMENTAL
Intervention: Both VE and GC
Number of subjects: 662
Study: 37733984

Group type: EXPERIMENTAL
Intervention: Symptom monitoring with electronic patient-reported outcomes (ePROs) via smartphone app
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Symptom monitoring with ePROs
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Endocrine therapy (ET)
Number of subjects: 250
Study: 37734031

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37734091

Group type: EXPERIMENTAL
Intervention: Remote monitoring
Number of subjects: 197

Group type: COMPARATOR
Intervention: In-office surveillance
Number of subjects: 197
Study: 37734093

Group type: EXPERIMENTAL
Intervention: Change of H.E.A.R.T RCT
Number of subjects: 38
Study: 37734293

Group type: EXPERIMENTAL
Intervention: CORALYS HF score
Number of subjects: 14699

Group type: EXPERIMENTAL
Intervention: Machine learning analysis
Number of subjects: 14699
Study: 37734399

Group type: COMPARATOR
Intervention: Perioperative chemotherapy (three preoperative and three postoperative 3-week cycles of intravenous 50 mg/m² epirubicin plus cisplatin or oxaliplatin plus fluorouracil or capecitabine or FLOT)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Trimodality therapy (preoperative radiotherapy with carboplatin plus paclitaxel [CROSS regimen])
Number of subjects: 362
Study: 37734804

Group type: EXPERIMENTAL
Intervention: Polypill regimen (5 mg ramipril, 50 mg atenolol, 12.5 mg hydrochlorothiazide, 20 mg simvastatin, 100 mg aspirin administered as two capsules once per day for 12 months)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Usual care (tailored guideline-recommended secondary prevention medications)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Polypill regimen
Number of subjects: 148
Study: 37734837

Group type: EXPERIMENTAL
Intervention: PET-driven consolidative strategy
Number of subjects: 0
Study: 37734856

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study: 37734857

Group type: EXPERIMENTAL
Intervention: CPAP treatment in high HB group
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: CPAP treatment in low HB group
Number of subjects: 727

Group type: COMPARATOR
Intervention: Usual care in low HB group
Number of subjects: 727
Study: 37734880

Group type: EXPERIMENTAL
Intervention: Reduced-dose prednisolone (0.5 mg/kg/day) plus rituximab (375 mg/m2)
Number of subjects: 140

Group type: COMPARATOR
Intervention: High-dose glucocorticoids plus rituximab
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Reduced-dose prednisolone plus rituximab
Number of subjects: 140
Study: 37734883

Group type: EXPERIMENTAL
Intervention: EmpaTeach intervention
Number of subjects: 97

Group type: COMPARATOR
Intervention: Corporal punishment
Number of subjects: 97
Study: 37734895

Group type: EXPERIMENTAL
Intervention: Patients with sensitive topics (n=474)
Number of subjects: 919

Group type: COMPARATOR
Intervention: Patients without sensitive topics (n=445)
Number of subjects: 919
Study: 37734896

Group type: EXPERIMENTAL
Intervention: REDUCE protocol (early de-resuscitation protocol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 0
Study: 37734899

Group type: EXPERIMENTAL
Intervention: Suspected risk factors (dialysis prescriptions, serum potassium testing frequency, patient characteristics, medication usage)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Serum potassium management patterns
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Serum potassium levels ≥6.0 and ≥6.5 mmol/L
Number of subjects: 300
Study: 37734951

Group type: EXPERIMENTAL
Intervention: Electromagnetic navigation bronchoscopy (ENB) with thin bronchoscopes, radial endobronchial ultrasound (rEBUS), and guide sheath (GS).
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Electromagnetic navigation bronchoscopy (ENB) with thin bronchoscopes.
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Electromagnetic navigation bronchoscopy (ENB).
Number of subjects: 479
Study: 37735023

Group type: EXPERIMENTAL
Intervention: Individualized group (n = 449) with additional 1.5 L PEG for high-risk patients
Number of subjects: 900

Group type: COMPARATOR
Intervention: Standard group (n = 451) without additional PEG
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Individualized group (n = 449) for high-risk patients
Number of subjects: 900

Group type: COMPARATOR
Intervention: Standard group (n = 451) for high-risk patients
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 900
Study: 37735271

Group type: EXPERIMENTAL
Intervention: InternalBrace™-augmented repair (ACL-IB)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: ACL reconstruction (ACL-R)
Number of subjects: 85

Group type: COMPARATOR
Intervention: InternalBrace™-augmented repair (ACL-IB) and ACL reconstruction (ACL-R)
Number of subjects: 85
Study: 37735274

Group type: EXPERIMENTAL
Intervention: Brain insulin action
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 37735385

Group type: EXPERIMENTAL
Intervention: Fish cartilage hydrolysate (FCH)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Fish cartilage hydrolysate (FCH) metabolites
Number of subjects: 33
Study: 37735443

Group type: EXPERIMENTAL
Intervention: Telehealth-enabled support (TEACH) intervention with real-time audit and feedback
Number of subjects: 9900

Group type: COMPARATOR
Intervention: Usual supervisor-led audit and feedback intervention
Number of subjects: 9900
Study: 37735517

Group type: EXPERIMENTAL
Intervention: Supported Osteoarthritis Self-Management Programme (SOASP)
Number of subjects: 143
Study: 37735543

Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 13
Study: 37735588

Group type: EXPERIMENTAL
Intervention: Adoptive transfer of vaccine-primed, ex vivo-expanded autologous peripheral blood T cells
Number of subjects: 19
Study: 37735634

Group type: EXPERIMENTAL
Intervention: mFFX (4 cycles) or Gemcitabine/Nab-Paclitaxel (6 doses)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: mFFX (2 cycles) or Gemcitabine/Nab-Paclitaxel (3 doses) + iHD-SBRT (35 to 55 Gy in 5 fractions) + mFFX (2 cycles) or Gemcitabine/Nab-Paclitaxel (3 doses)
Number of subjects: 256

Group type: COMPARATOR
Intervention: mFFX (4 additional cycles) or Gemcitabine/Nab-Paclitaxel (6 additional doses)
Number of subjects: 256
Study: 37735664

Group type: EXPERIMENTAL
Intervention: Concurrent exercise training during adjuvant chemotherapy
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Baseline, post-intervention, and 3-month follow-up assessments
Number of subjects: 8
Study: 37735668

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) (0.05 ml; cell concentration: 1.5 × 10^6 cells)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs)
Number of subjects: 5
Study: 37735690

Group type: EXPERIMENTAL
Intervention: Adaptive assist-as-needed (AAN) control using the Lokomat
Number of subjects: 27
Study: 37735706

Group type: EXPERIMENTAL
Intervention: Deliberative engagement process
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preparation of staff for deliberations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Briefing materials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Creating a comfortable environment for staff
Number of subjects: 0
Study: 37735756

Group type: EXPERIMENTAL
Intervention: DC:Ad-S vaccine administered 7 to 30 days prior to stem cell collection and 20 to 34 days after ASCT
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: DC:Ad-S vaccine
Number of subjects: 14
Study: 37735841

Group type: EXPERIMENTAL
Intervention: GL-Asp (0.2 U/kg)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: GL-Lis (0.2 U/kg)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: GL-Gla (0.5 U/kg)
Number of subjects: 187
Study: 37736522

Group type: EXPERIMENTAL
Intervention: Daily cannabis use in PLWH
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: HIV chronicity (years since HIV diagnosis)
Number of subjects: 48
Study: 37736603

Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair
Number of subjects: 115
Study: 37736711

Group type: EXPERIMENTAL
Intervention: IV dexamethasone 8 mg in 500 mL normal saline
Number of subjects: 200

Group type: COMPARATOR
Intervention: 500 mL normal saline
Number of subjects: 200
Study: 37736793

Group type: EXPERIMENTAL
Intervention: Ceramide nanoLiposomes (CNL)
Number of subjects: 15
Study: 37736959

Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry juice
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 37736966

Group type: EXPERIMENTAL
Intervention: Conditional-collective-community-based incentives (C3Is) provided to community groups in HRUCs based on reduction in polio vaccine refusals.
Number of subjects: 0
Study: 37736981

Group type: EXPERIMENTAL
Intervention: Simple linear regression predicting X-nuclear transmit gain based on proton body coil data.
Number of subjects: 156
Study: 37737050

Group type: EXPERIMENTAL
Intervention: HUBER rehabilitation group (HUB) with physiotherapy, balneotherapy and HUBER exercises
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard rehabilitation group (STAND) with physiotherapy, balneotherapy and cycloergometer exercises
Number of subjects: 70
Study: 37737114

Group type: EXPERIMENTAL
Intervention: Lullabies sung by mothers
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 51

Group type: COMPARATOR
Intervention: Routine care with no music
Number of subjects: 51
Study: 37737132

Group type: EXPERIMENTAL
Intervention: MRI and CT measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline pulmonary function
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imaging texture-features
Number of subjects: 0
Study: 37737952

Group type: EXPERIMENTAL
Intervention: IXEQ4W (80 mg every 4 weeks, starting dose 160 mg)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: IXEQ4W (overall study population)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo (overall study population)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: IXEQ4W
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo (switched to IXEQ4W)
Number of subjects: 147
Study: 37737962

Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta-1a (IM IFNβ-1a) exposure during early pregnancy
Number of subjects: 302

Group type: COMPARATOR
Intervention: Control group from the Metropolitan Atlanta Congenital Defects Program (MACDP)
Number of subjects: 302
Study: 37737966

Group type: EXPERIMENTAL
Intervention: Naloxone nasal spray administration by lay citizens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard emergency response
Number of subjects: 0
Study: 37738028

Group type: EXPERIMENTAL
Intervention: PAC-1 and entrectinib
Number of subjects: 6
Study: 37738052

Group type: EXPERIMENTAL
Intervention: Usual care augmented by telemedicine decision support (n=13,274)
Number of subjects: 26254

Group type: COMPARATOR
Intervention: Usual care (control group; n=12,980)
Number of subjects: 26254
Study: 37738081

Group type: EXPERIMENTAL
Intervention: ThoughtFullChat app (text-based coaching with certified mental health professionals)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 392
Study: 37738088

Group type: EXPERIMENTAL
Intervention: Fludarabine (Flu), thiotepa (Thio), and busulfan (Bu)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Fludarabine (Flu), thiotepa (Thio), and treosulfan (Treo)
Number of subjects: 191
Study: 37738125

Group type: EXPERIMENTAL
Intervention: Nilotinib (230 mg/m2 twice daily)
Number of subjects: 59
Study: 37738155

Group type: EXPERIMENTAL
Intervention: InCharge Health
Number of subjects: 293

Group type: COMPARATOR
Intervention: HU Toolbox
Number of subjects: 293
Study: 37738153

Group type: EXPERIMENTAL
Intervention: Infected patients with CRAb
Number of subjects: 842

Group type: COMPARATOR
Intervention: Non-infected patients
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Bacteremia
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Other types of infection
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: CG2 strains
Number of subjects: 842

Group type: EXPERIMENTAL
Intervention: Non-CG2 strains
Number of subjects: 842
Study: 37738237

Group type: EXPERIMENTAL
Intervention: selfBACK app adjunct to usual care
Number of subjects: 461

Group type: COMPARATOR
Intervention: usual care only
Number of subjects: 461
Study: 37738323

Group type: EXPERIMENTAL
Intervention: Digital Health interventions in Cancer and Palliative Care
Number of subjects: 0
Study: 37738329

Group type: EXPERIMENTAL
Intervention: TRK-250, a Novel siRNA-Based Oligonucleotide
Number of subjects: 0
Study: 37738368

Group type: EXPERIMENTAL
Intervention: Near-Infrared Photobiomodulation Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37738626

Group type: EXPERIMENTAL
Intervention: FPDMM patients with RUNX1 variants
Number of subjects: 214
Study: 37738655

Group type: EXPERIMENTAL
Intervention: TCRαβ/CD19 cell depletion
Number of subjects: 213
Study: 37738676

Group type: EXPERIMENTAL
Intervention: Immune monitoring-guided antiviral prophylaxis
Number of subjects: 193

Group type: COMPARATOR
Intervention: Fixed duration of antiviral prophylaxis (180 days for CMV-seronegative or 90 days for CMV-seropositive)
Number of subjects: 193
Study: 37739167

Group type: EXPERIMENTAL
Intervention: Bazedoxifene (BZA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37739426

Group type: EXPERIMENTAL
Intervention: Iontophoresis-assisted CXL
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Iontophoresis-assisted CXL (truly progressive disease)
Number of subjects: 11
Study: 37739466

Group type: EXPERIMENTAL
Intervention: Vitamin C (6 g) and Vitamin D
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 90
Study: 37739475

Group type: EXPERIMENTAL
Intervention: Prehospital assessment unit (PAU)
Number of subjects: 10849

Group type: COMPARATOR
Intervention: Non-PAU assessed patients (Control)
Number of subjects: 10849
Study: 37739476

Group type: EXPERIMENTAL
Intervention: Virtual reality-based recreational experiences offered during hospitalisation
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard care without VR-based recreational experiences
Number of subjects: 124
Study: 37739573

Group type: EXPERIMENTAL
Intervention: Arimoclomol 400 mg three times daily (1200 mg/day) for 20 months
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Arimoclomol
Number of subjects: 150
Study: 37739574

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation plus exercise (n=70)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Sham cognitive rehabilitation plus exercise (n=71)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation plus sham exercise (n=76)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Sham cognitive rehabilitation and sham exercise (n=67)
Number of subjects: 311
Study: 37739572

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg orally per day
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 78
Study: 37739684

Group type: EXPERIMENTAL
Intervention: Individually tailored nutritional guidance provided by a clinical nutritionist
Number of subjects: 63
Study: 37739681

Group type: EXPERIMENTAL
Intervention: Diarrhoea
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Constipation
Number of subjects: 100
Study: 37739688

Group type: EXPERIMENTAL
Intervention: Intensive dietary intervention focusing on healthy eating according to Norwegian food-based dietary guidelines
Number of subjects: 383
Study: 37739706

Group type: EXPERIMENTAL
Intervention: Hand Grip (HG) dynamometer measurement for muscle strength
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Assessment of malnutrition according to GLIM criteria
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Screening for sarcopenia in primary care
Number of subjects: 341
Study: 37739719

Group type: EXPERIMENTAL
Intervention: Geriatric Nutritional Risk Index (GNRI) scores ≤98
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Geriatric Nutritional Risk Index (GNRI)
Number of subjects: 224
Study: 37739769

Group type: EXPERIMENTAL
Intervention: Conjunctival-limbal autograft (CLAu)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Mini-simple limbal epithelial transplantation (mini-SLET)
Number of subjects: 61
Study: 37739792

Group type: EXPERIMENTAL
Intervention: Favipiravir (1800 mg twice a day on day 1, 800 mg twice a day on days 2 to 5)
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: Favipiravir (average Cmin ≥20 µg/mL)
Number of subjects: 1246

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1246
Study: 37739939

Group type: EXPERIMENTAL
Intervention: Guadecitabine 30, 45 or 60 mg/m² combined with ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ipilimumab alone (control not explicitly mentioned)
Number of subjects: 0
Study: 37740001

Group type: EXPERIMENTAL
Intervention: Expect Adderall/receive placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Expect Adderall/receive 200 mg caffeine
Number of subjects: 121

Group type: COMPARATOR
Intervention: Expect/receive no drug (control)
Number of subjects: 121
Study: 37740107

Group type: EXPERIMENTAL
Intervention: SRP plus adjunctive sodium hypochlorite/amino acid and xHyA gels
Number of subjects: 48

Group type: COMPARATOR
Intervention: SRP (control)
Number of subjects: 48
Study: 37740111

Group type: EXPERIMENTAL
Intervention: Autologous cell therapy (ACT)
Number of subjects: 1700